N-(3-((6-(benzylamino)pyrimidin-4-yl)oxy)phenyl)-2-chloroacetamide

ID: ALA5284723

Max Phase: Preclinical

Molecular Formula: C19H17ClN4O2

Molecular Weight: 368.82

Names and Identifiers

Canonical SMILES:  O=C(CCl)Nc1cccc(Oc2cc(NCc3ccccc3)ncn2)c1

Standard InChI:  InChI=1S/C19H17ClN4O2/c20-11-18(25)24-15-7-4-8-16(9-15)26-19-10-17(22-13-23-19)21-12-14-5-2-1-3-6-14/h1-10,13H,11-12H2,(H,24,25)(H,21,22,23)

Standard InChI Key:  SWAPCFYOLJWGBA-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
   -3.2075   -0.1756    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9226   -0.5871    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6316   -0.1736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6329    0.6471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9178    1.0585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2052    0.6429    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4986   -0.5892    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7859   -0.1819    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0770   -0.5954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3655   -0.1861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3471   -0.6018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3483   -1.4268    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3703   -1.8319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0829   -1.4163    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0586   -0.1925    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.7686   -0.6040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4850   -0.1949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1926   -0.6106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1876   -1.4336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4749   -1.8407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7649   -1.4291    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9054   -0.2036    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9128    0.6150    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6255    1.0221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6329    1.8407    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    3.2051    1.0307    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  1  6  1  0
  1  7  1  0
  7  8  1  0
  8  9  1  0
 10  9  2  0
 11 10  1  0
 12 11  2  0
 13 12  1  0
 14 13  2  0
 14  9  1  0
 11 15  1  0
 15 16  1  0
 17 16  1  0
 18 17  2  0
 18 19  1  0
 20 19  2  0
 16 21  2  0
 21 20  1  0
 18 22  1  0
 23 22  1  0
 23 24  1  0
 25 24  1  0
 23 26  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA5284723

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 368.82

Molecular Weight (Monoisotopic): 368.1040

AlogP: 4.06

#Rotatable Bonds: 7

Polar Surface Area: 76.14

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.08

CX Basic pKa: 4.71

CX LogP: 3.71

CX LogD: 3.71

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.61

Np Likeness Score: -1.69

References

1. Kim DR, Orr MJ, Kwong AJ, Deibler KK, Munshi HH, Bridges CS, Chen TJ, Zhang X, Lacorazza HD, Scheidt KA..  (2023)  Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.,  14  (5): [PMID:37197477] [10.1021/acsmedchemlett.3c00029]

Source

Source(1):

• Scientific Literature